• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome.

作者信息

Huguenin P, Glanzmann C, Taussky D, Lütolf U M, Schmid S, Moe K

机构信息

Radiation Oncology Department, University Hospital Zurich, Switzerland.

出版信息

Strahlenther Onkol. 1998 Aug;174(8):397-402. doi: 10.1007/BF03038560.

DOI:10.1007/BF03038560
PMID:9739379
Abstract

PURPOSE

To assess the survival rate, the probability of local control, the patterns of relapse and late sequelae including self-reported quality of life in patients treated with hyperfractionated radiotherapy (RT) and simultaneous CDDP chemotherapy for stage-III to stage-IV carcinomas of the head and neck.

METHODS

From 1988 to 1994, 64 patients (median age 55.5 years) with carcinomas of different subsites, excluding the nasopharynx, were treated in a pilot study with 1.2 Gy bid (6 h interval; total dose 74.4 Gy) and simultaneous CDDP (20 mg/m2 daily, 5 days in week 1 and 5) and followed at regular intervals. Overall survival and local control, as well as the rates of late toxicity, were estimated using the actuarial method. Median follow-up was 3.3 years for all and 5.2 years for surviving patients. To assess the quality of life, the EORTC QLQ-C 30 questionnaire and the H&N35 module questionnaire were sent to the patients surviving with no evidence of disease or second primary tumors; they were answered by 15/23 (67%).

RESULTS

Overall survival was 37% at 5 years, whereas disease-specific survival was 59%. Twenty-three patients died from uncontrolled head and neck cancer. Second primary tumors were observed in 13 patients, most frequently in the lung. Local control without salvage surgery was 74% at 5 years for all subsites and stages, and loco-regional disease-free survival was 72%. Eleven patients developed distant metastases, which was the only site of failure in 6 cases. Salvage surgery was successful in 2 cases. The actuarial estimates of > or = grade-3 late toxicity was 4% for the mandibular bone and 23% for dysphagia, and 50% of the patients experienced a permanent xerostomy. Self-reported global quality of life in surviving patients was good (mean 68 points on a scale 0 to 100); consequences of impaired salivary function had most impact on nutritional and social aspects.

CONCLUSIONS

Hyperfractionated RT with concomitant CDDP is well tolerated and highly efficient in controlling moderately advanced to advanced cancers of the head and neck. Second primary tumors are the main cause of death after 3 years and were observed outside of the irradiated area, most frequently in the lung. Even after RT of large volumes to a high dose, salvage surgery can be successfully performed in individual cases. Self-reported quality of life of surviving patients is good, despite xerostomy-associated nutritional difficulties.

摘要

相似文献

1
Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome.
Strahlenther Onkol. 1998 Aug;174(8):397-402. doi: 10.1007/BF03038560.
2
Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.术前顺铂和加速超分割放疗可使晚期头颈癌患者产生较高的肿瘤反应率和控制率。
Am J Surg. 1995 Nov;170(5):512-6. doi: 10.1016/s0002-9610(99)80342-0.
3
Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.顺铂和紫杉醇同步进行的积极放化疗联合加速超分割放疗用于局部晚期头颈部肿瘤。一项I-II期试验的结果
Strahlenther Onkol. 2003 Oct;179(10):673-81. doi: 10.1007/s00066-003-1106-0.
4
Concurrent platinum-based chemotherapy and hyperfractionated radiotherapy with late intensification in advanced head and neck cancer.晚期头颈癌同步铂类化疗与超分割放疗并序贯后程强化治疗
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):721-9. doi: 10.1016/s0360-3016(97)00366-0.
5
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.同步使用顺铂可显著提高晚期头颈癌超分割放疗的局部区域控制率。
J Clin Oncol. 2004 Dec 1;22(23):4665-73. doi: 10.1200/JCO.2004.12.193. Epub 2004 Nov 8.
6
Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients.III期和IV期头颈癌患者同步铂类化疗与加速超分割放疗后的复发模式
Am J Surg. 1997 Nov;174(5):532-5. doi: 10.1016/s0002-9610(97)81724-2.
7
Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).同期顺铂和超分割放疗局部晚期头颈部癌:随机 III 期试验(SAKK 10/94)的 10 年随访结果。
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31. doi: 10.1016/j.ijrobp.2010.11.067. Epub 2011 Feb 16.
8
Intensification regimen 2 for advanced head and neck squamous cell carcinomas.晚期头颈部鳞状细胞癌的强化治疗方案2
Arch Otolaryngol Head Neck Surg. 1999 Dec;125(12):1313-8. doi: 10.1001/archotol.125.12.1313.
9
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.强化超分割加速放疗限制了同步化疗的额外获益——一项针对晚期头颈癌的德国多中心随机试验结果
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71. doi: 10.1016/s0360-3016(01)01544-9.
10
Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone.III-IV期头颈癌同步加量放疗与化疗联合应用:毒性及治疗结果与单纯放疗的比较
Ann Oncol. 1997 Jul;8(7):681-4. doi: 10.1023/a:1008260720076.

引用本文的文献

1
Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin.局部晚期头颈部鳞状细胞癌患者同期放化疗中每周一次与每 3 周一次顺铂治疗的生活质量。
Cancer Med. 2022 Nov;11(21):3939-3948. doi: 10.1002/cam4.4715. Epub 2022 Mar 28.
2
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.治疗口腔和口咽癌的干预措施:化疗。
Cochrane Database Syst Rev. 2021 Dec 20;12(12):CD006386. doi: 10.1002/14651858.CD006386.pub4.
3
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.

本文引用的文献

1
[The radiochemotherapy of advanced head-neck tumors--what is certain?].
Strahlenther Onkol. 1996 Aug;172(8):409-16.
2
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.一项关于头颈部不可切除鳞状细胞癌的随机试验的五年随访结果:交替放疗与化疗联合方案与单纯放疗方案的比较
J Natl Cancer Inst. 1996 May 1;88(9):583-9. doi: 10.1093/jnci/88.9.583.
3
Radiotherapy plus chemotherapy for head and neck cancer.
N Engl J Med. 1993 Feb 25;328(8):579-80.
4
两种原发性放化疗方案治疗晚期头颈部鳞状细胞癌的急性毒性比较。
Ann Surg Oncol. 2012 Jun;19(6):1980-7. doi: 10.1245/s10434-012-2219-4.
4
Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?放化疗相关性艰难梭菌相关性腹泻:对放化疗可行性的一个被低估的问题?
Radiat Oncol. 2011 Aug 1;6:89. doi: 10.1186/1748-717X-6-89.
5
Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies.癌症患者的放射性骨坏死:基于治疗的频率、当前管理策略和未来研究的证据基础。
Support Care Cancer. 2010 Aug;18(8):1089-98. doi: 10.1007/s00520-010-0898-6. Epub 2010 Jun 6.
6
PET/CT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison.PET/CT 分期后行调强放疗(IMRT)可改善局部晚期咽癌的治疗效果:一项配对比较研究。
Radiat Oncol. 2007 Jun 9;2:22. doi: 10.1186/1748-717X-2-22.
[The systematics of acute and chronic radiation sequelae].[急性和慢性辐射后遗症的系统分类]
Strahlenther Onkol. 1993 Feb;169(2):83-95.
5
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.欧洲癌症研究与治疗组织QLQ-C30:一种用于肿瘤学国际临床试验的生活质量评估工具。
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
6
An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer.头颈部癌辅助化疗的随机对照试验综述。
Br J Cancer. 1995 Jan;71(1):83-91. doi: 10.1038/bjc.1995.17.
7
Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group.开发一个用于头颈癌患者生活质量评估的欧洲癌症研究与治疗组织(EORTC)问卷模块。EORTC生活质量研究小组。
Acta Oncol. 1994;33(8):879-85. doi: 10.3109/02841869409098450.
8
Patient self-reported and clinician-rated quality of life in head and neck cancer patients: a cross-sectional study.头颈癌患者的患者自我报告及临床医生评定的生活质量:一项横断面研究。
Eur J Cancer B Oral Oncol. 1995 Jul;31B(4):235-41. doi: 10.1016/0964-1955(95)00010-f.
9
Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience.头颈部癌患者的第二原发性恶性肿瘤:基于放射治疗肿瘤学组(RTOG)经验的发病率、对生存的影响及意义
Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):449-56. doi: 10.1016/0360-3016(89)90094-1.
10
Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17.
Cancer. 1990 Nov 1;66(9):1861-8. doi: 10.1002/1097-0142(19901101)66:9<1861::aid-cncr2820660902>3.0.co;2-i.